Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | PDE2A | O00408 | 2/20 | 0.36 |
| ▸ | KIF11 | P52732 | 4/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.32 |
| ▸ | CYP8B1 | Q9UNU6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30489827 | 1.00 | L3MBTL1 (0.38) | L3MBTL1PDE2AKIF11HSD17B10ALDH1A1 | |
| SCHEMBL31312323 | 0.80 | KIF11 (0.35) | L3MBTL1KIF11HSD17B10MAPTATM | |
| SCHEMBL9796484 | 0.80 | MEN1 (0.36) | L3MBTL1KIF11MAPTATM | |
| SCHEMBL8754421 | 0.80 | PDE2A (0.39) | L3MBTL1PDE2AKIF11HSD17B10ALDH1A1 | |
| SCHEMBL11566523 | 0.80 | KIF11 (0.39) | L3MBTL1KIF11HSD17B10ALDH1A1MAPT | |
| SCHEMBL2799236 | 0.78 | L3MBTL1 (0.40) | L3MBTL1KIF11MAPTATM | |
| SCHEMBL29410754 | 0.77 | CSNK2A2 (0.36) | HSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL9796224 | 0.76 | KIF11 (0.38) | KIF11 | |
| SCHEMBL6339412 | 0.76 | PDE2A (0.36) | L3MBTL1PDE2AKIF11HSD17B10ALDH1A1 | |
| SCHEMBL8722519 | 0.76 | ACHE (0.39) | L3MBTL1PDE2AKIF11HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116406271-A | Bicyclic compounds | 江苏先声药业有限公司 | 2023-07-07 | — | — | CN | disclosed |
| US-8524738-B2 | Quinolinones and quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-8524738-B2 | Quinolinones and quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-8329694-B2 | Quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-8329694-B2 | Quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-8329694-B2 | Quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-23 | — | — | US | disclosed |
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-23 | — | — | US | disclosed |
| EP-2468743-A1 | Nitrogen-containing bicyclic compounds useful as antibacterial agents | Toyama Chemical Co., Ltd. (JP) | 2012-06-27 | — | — | EP | disclosed |
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
| EP-1900732-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-03-19 | — | — | EP | disclosed |
| US-4997840-A | Quinolone sulphonates having antihypertensive activity | THE BOOTS COMPANY, PLC (GB) | 1991-03-05 | — | — | US | disclosed |
| EP-0330340-A1 | Therapeutic agents | The Boots Company PLC (GB) | 1989-08-30 | — | — | EP | disclosed |
| WO-1989007593-A1 | THERAPEUTIC AGENTS | THE BOOTS COMPANY PLC (GB) | 1989-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | ROS1, NOX1, ARG1 | L3MBTL1 357/4885PDE2A 4173/4885KIF11 3704/4885 |
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | NQO2, ASNS, NDUFS1 | L3MBTL1 4408/4885PDE2A 2901/4885KIF11 4264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.